(ALINS) Intrasense - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0011179886
ALINS: Medical, Imaging, Software
Intrasense SA (ALINS:PA) specializes in developing advanced software solutions for medical imaging visualization and analysis under the Myrian brand. The company provides a suite of tools tailored for healthcare professionals, researchers, and industrial clients. Its product portfolio includes Myrian Imaging Layer, a multimodal visualization platform; Myrian Studio, a development environment for medical imaging applications; and Myrian Clinical Apps, a range of specialized clinical applications such as Myrian XP-Breast, XP-Prostate, and XP-Lung, designed for advanced post-processing and diagnostics. The company also focuses on biomarker development and AI-driven solutions for medical imaging. Founded in 2004 and headquartered in Montpellier, France, Intrasense operates at the intersection of healthcare and technology, serving clients globally.
From a technical standpoint, Intrasense shares are trading at €0.25 with a 20-day average volume of 16,960. The stock shows a flat trend with SMA 20 and SMA 50 at €0.25, while the SMA 200 is slightly higher at €0.28. The ATR of €0.01 indicates low volatility. Fundamentally, the company has a market cap of €12.90M, a P/B ratio of 2.57, and a P/S ratio of 5.53, reflecting its position as a small-cap healthcare technology firm.
Additional Sources for ALINS Stock
ALINS Stock Overview
| Market Cap in USD | 14m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception |
ALINS Stock Ratings
| Growth 5y | -44.5% |
| Fundamental | -37.5% |
| Dividend | 0.0% |
| Rel. Strength Industry | -13.8 |
| Analysts | - |
| Fair Price Momentum | 0.22 EUR |
| Fair Price DCF | - |
ALINS Dividends
No Dividends PaidALINS Growth Ratios
| Growth Correlation 3m | -37.6% |
| Growth Correlation 12m | -64.4% |
| Growth Correlation 5y | -87.2% |
| CAGR 5y | -2.56% |
| CAGR/Max DD 5y | -0.03 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | -7.36 |
| Beta | -0.50 |
| Volatility | 33.87% |
| Current Volume | 5.6k |
| Average Volume 20d | 14.9k |
As of March 16, 2025, the stock is trading at EUR 0.25 with a total of 5,580 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -1.20%, over three months by -8.86% and over the past year by -13.03%.
Probably not. Based on ValueRay Fundamental Analyses, Intrasense (PA:ALINS) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.53 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALINS as of March 2025 is 0.22. This means that ALINS is currently overvalued and has a potential downside of -12%.
Intrasense has no consensus analysts rating.
According to ValueRays Forecast Model, ALINS Intrasense will be worth about 0.2 in March 2026. The stock is currently trading at 0.25. This means that the stock has a potential downside of -4%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 0.2 | -20% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.2 | -4% |